Novavax Gets FDA Approval To Resume Testing 2 Vaccines

(Reuters) - Novavax cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ...
Novavax (NASDAQ:NVAX) shares lost ~12% in the premarket on Tuesday after the Gaithersburg, MD-based biotech, with its Q3 2024 ...
Advanced preparation for Sanofi to assume lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine for 2025-2026 ...
The vaccine maker posted revenue of $84.5 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $57.3 million. Novavax expects full-year revenue in the ...
Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...
Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...
They may be eligible for Novavax, which is a different COVID vaccine. Novavax is approved for children aged 12 and ...